VXRT News and Press, Vaxart Inc. From 04/27/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology company Vaxart  (NASDAQ: VXRT ), as the name implies, is known for developing vaccines. There are other, more famous coronavirus vaccine makers out there, but VXRT stock is cheap and m...

Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing ...

SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to ...

A new poll, commissioned by Vaxart (VXRT), found that 70% would prefer a vaccine given as a pill than an injection.While 23% of respondents said they didn't plan on getting a COVID-19 vaccine, about one-third said they would if given the option of a vaccine pill.The national survey included 1...

Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Nearly 19 million mo...

Some stock traders have short attention spans. Shares can have dramatic rises over the course of months, only to be forgotten at the first sign of trouble. This is especially true in the biotech world, where data from a clinical trial can be the difference between billions in revenue or...

Vaxart is one of over 40 biotechs still developing a COVID vaccine. The company offers a unique oral vaccine platform that requires no needles. The share price remains volatile while the company is a long way from commercialization. This is a company worth following but not si...

Let's face it, we all wish we could have bought and held a stock that ended up rising 50 or 100 times in value over the last decade. Unfortunately, capturing that type of gain typically means investing while the company is still small and its outcome is uncertain. Trillium Therapeutic...

When you think of COVID-19 vaccines, shots probably come to mind. However, a small biotech, Vaxart (NASDAQ: VXRT) , is developing an oral COVID-19 vaccine candidate. In this Motley Fool Live video recorded on March 24, 2021 , Motley Fool contributors Keith Speights and Bria...

There are many ways to examine a stock's potential. For biotech companies, I usually look at their pipelines, revenue prospects, and various financial metrics. But today, I'm going to look at something different: what other investors say about two particular stocks. And the best way to do t...